NASDAQ · SABS
SAB Biotherapeutics, Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
Price chart by TradingView
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for SABS: Nov 05, 2026
SAB Biotherapeutics, Inc. Common Stock is expected to report earnings on 11/05/2026 before market open. The report will be for the fiscal Quarter ending Sep 2026. According to Zacks Investment Research, based on 3 analysts' forecasts, the consensus EPS forecast for the quarter is $-0.27. The reported EPS for the same quarter last year was $-0.21.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $-0.27 | $-0.24 | $-0.29 | 3 |
| Dec 2026 | $-0.28 | $-0.24 | $-0.31 | 3 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
MarketBeat · RTTNews · Fintel · Zacks- MarketBeat · Oct 23, 1:02 AM EDTSAB Biotherapeutics Highlights Diabetes Trial Progress, Human Antibody PlatformPromising Upsides on these Biotech Penny StocksExecutives from Healios and SAB Biotherapeutics (NASDAQ:SABS) outlined their approaches to developing scalable biologic therapies during a Chardan discussion focused on complex treatments designed for commercial manufacturing. Heali
- RTTNews · Oct 13, 9:05 AM EDTSAB Bio Wins FDA Fast Track Status For SAB-142 In Type 1 Diabetes; Stock Up(RTTNews) – SAB Biotherapeutics, Inc. (SABS) announced that the U.S. FDA has granted Fast Track designation to SAB-142 for the treatment of patients with Stage 3 Type 1 Diabetes. The designation is intended to facilitate the development and review of therapies that address seriou
- MarketBeat · Aug 7, 8:03 AM EDTSAB Biotherapeutics Q2 Earnings Call HighlightsPromising Upsides on these Biotech Penny StocksSAB Biotherapeutics (NASDAQ:SABS) said its registrational Phase IIb SAFEGUARD trial of SAB-142 in newly diagnosed Stage 3 Type 1 diabetes remains on track to complete enrollment in the fourth quarter of 2026, with top-line data expec
- Fintel · May 22, 8:02 PM EDTCitigroup Initiates Coverage of SAB Biotherapeutics (SABS) with Buy RecommendationFintel reports that on May 22, 2026, Citigroup initiated coverage of SAB Biotherapeutics (NasdaqCM:SABS) with a Buy recommendation. Analyst Price Forecast Suggests 154.33% Upside
- Fintel · May 20, 5:19 PM EDTJefferies Initiates Coverage of SAB Biotherapeutics (SABS) with Buy RecommendationFintel reports that on May 20, 2026, Jefferies initiated coverage of SAB Biotherapeutics (NasdaqCM:SABS) with a Buy recommendation. Analyst Price Forecast Suggests 172.96% Upside
- MarketBeat · May 12, 1:14 PM EDTSAB Biotherapeutics Q1 Earnings Call HighlightsPromising Upsides on these Biotech Penny StocksSAB Biotherapeutics (NASDAQ:SABS) said its lead type 1 diabetes candidate, SAB-142, remains on track in a registrational Phase 2b trial, as the clinical-stage biopharmaceutical company reported a wider first-quarter loss alongside hi
- Fintel · Jan 7, 7:03 PM ESTUBS Initiates Coverage of SAB Biotherapeutics (SABS) with Buy RecommendationFintel reports that on January 7, 2026, UBS initiated coverage of SAB Biotherapeutics (NasdaqCM:SABS) with a Buy recommendation. Analyst Price Forecast Suggests 148.89% Upside
- Fintel · Dec 19, 7:06 PM ESTGuggenheim Initiates Coverage of SAB Biotherapeutics (SABS) with Buy RecommendationFintel reports that on December 19, 2025, Guggenheim initiated coverage of SAB Biotherapeutics (NasdaqCM:SABS) with a Buy recommendation. Analyst Price Forecast Suggests 127.24% Upside
- Fintel · Dec 18, 7:06 PM ESTChardan Capital Maintains SAB Biotherapeutics (SABS) Buy RecommendationFintel reports that on December 18, 2025, Chardan Capital maintained coverage of SAB Biotherapeutics (NasdaqCM:SABS) with a Buy recommendation. Analyst Price Forecast Suggests 129.26% Upside
- Fintel · Sep 17, 6:19 PM EDTLeerink Partners Initiates Coverage of SAB Biotherapeutics (SABS) with Outperform RecommendationFintel reports that on September 17, 2025, Leerink Partners initiated coverage of SAB Biotherapeutics (NasdaqCM:SABS) with a Outperform recommendation.
- Zacks · Aug 7, 10:00 AM EDTSAB Biotherapeutics, Inc. (SABS) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 ReleaseSAB Biotherapeutics (SABS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Quiver Quantitative · Jul 22, 8:20 AM EDTNew Analyst Forecast: $SABS Given $9.0 Price TargetWe just received data on a new analyst forecast for $SABS. Emily Bodnar from HC Wainwright & Co. set a price target of 9.0 for SABS.
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Company profile by TradingView
Financials
Loading fundamental data…
Fundamental data by TradingView
More headlines
More stories for SAB Biotherapeutics, Inc. from TradingView. Coverage varies.
Loading related news…
Related news by TradingView
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.